FDA Panel Reviews VTE Risk for Some OCs
January 1, 2012|ObGyn
Author and Disclosure Information
From a Meeting of the FDA's Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee
Relatives of several young women who had fatal pulmonary emboli while on Yaz testified during the open public hearing portion of the meeting, calling for the withdrawal of drospirenone-containing contraceptives from the market, as did several women's health advocates who also testified.
The FDA usually follows the recommendations of its advisory panels, which are not binding. Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.
